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Metastasis-inducing S100A4 protein is associated with the disease
activity of rheumatoid arthritis
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Objectives. To evaluate the association between metastasis-inducing protein S100A4 and disease activity in patients with RA, and to
demonstrate the effect of TNF- blocking therapy on plasma levels of S100A4 in these patients.
Methods. Plasma levels of the S100A4 protein were analysed in 40 anti-TNF- naive patients with active RA. Of the 40 patients, 25 were
treated with adalimumab and monitored over time. The conformational form of S100A4 was analysed using size-exclusion gel chromatog-
raphy. TNF- mRNA expression and protein synthesis were analysed by RT–PCR and ELISA, respectively.
Results. Baseline levels of S100A4 were significantly correlated with disease activity in RA patients (r¼ 0.41; P < 0.01). After 12 weeks of
treatment with adalimumab, there was an obvious shift in the conformations of S100A4 from the multimeric to the dimeric forms, whereas the
total levels of the S100A4 protein remained unchanged. This suggests that the bioactive (multimer) S100A4 may decline in response to
successful treatment with adalimumab. In addition, we showed significant up-regulation of TNF- mRNA (P< 0.01), and protein release to the
cell culture medium of monocytes stimulated with the S100A4 multimer compared with those treated with the dimer and to the unstimulated
monocytes (P< 0.001).
Conclusions. This is the first study to show that the levels of the S100A4 protein are correlated with RA disease activity. Furthermore,
only the bioactive form, but not the total amount of S100A4, decreases after successful TNF- blocking therapy in patients with RA. These
data support an important role for the S100A4 multimer in the pathogenesis of RA.
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Introduction
RA is a systemic, autoimmune, inflammatory disease character-
ized by persistent inflammation of synovial joints and progressive
joint destruction. The exact aetiopathogenesis of RA is still
uncertain. Nevertheless, several different cell types, such as
T cells, B cells, macrophages and synovial fibroblasts have been
shown to produce a wide range of cytokines and inflammatory
mediators that contribute to the tissue-destructive process of the
disease [1–3]. TNF-, which is secreted by most of these cells, is
one of the central drivers of RA’s pathology [4, 5]. As a result,
TNF- inhibitors have been introduced as an effective treatment
for patients with active RA [6, 7].
The S100 protein family represents the largest group of
calcium-binding proteins, and it is known to be involved in diverse
biological regulatory activities [8]. The best-known members of
the family, S100A8/A9 and S100A12, have been localized to
inflammation sites and proposed to act as alarmins—endogenous
molecules that signal tissue and cellular damage [9, 10]. S100
alarmins can be released, exert cytokine-like activities and trigger
a variety of intracellular signalling pathways [9, 10]. Both S100A8/
A9 and S100A12 have been previously found to be up-regulated in
inflamed synovial tissue, SF and in circulating blood of patients
with RA. In addition, a tight association between these proteins
and the activity of the disease has been recently demonstrated
in patients with several arthritides [11–14]. Furthermore, the
levels of both alarmins decrease in response to different
anti-inflammatory therapies and become up-regulated even
weeks before the clinical appearance of relapse in patients with
previously well-controlled disease [15, 16]. In addition, the decline
in both S100 proteins in the synovial tissue and in the bloodstream
has also been demonstrated in RA patients who were treated with
the TNF- inhibitors, infliximab or etanercept [14, 16, 17].
We have recently reported that another member of the S100
family, S100A4, is significantly up-regulated in activated synovial
fibroblasts, hyperplastic synovial tissue and in SF and plasma of
RA patients [18–21]. S100A4, also known as calvasculin,
fibroblast-specific protein (FspI) or metastasin (Mts1), was first
described 20 years ago as a metastasis-specific gene product [22].
Since then, it has become evident that S100A4 contributes not
only to the regulation of tumour progression and metastasis (for
review see Helfman et al. [23]), but that it may also participate in
the process of inflammation and cartilage destruction [24, 25].
Therefore, the aim of this study was to evaluate the association
between the S100A4 protein and disease activity, and to measure
the effect of the TNF- inhibitor adalimumab on the plasma
levels of S100A4 protein in patients with active RA.
Methods
Patients
Forty patients with active RA were enrolled in this study
[34 females and 6 males; mean (S.D.) age 50.6 13.3 years]. All
patients fulfilled the revised criteria of the ACR for the diagnosis
of RA [26]. Twenty-five of these patients (21 females and 4 males;
mean age 43.7 10.3 years) were treated with the anti-TNF-
agent adalimumab and then followed for the following
12 weeks. Adalimumab was administrated subcutaneously in a
standard dose of 40mg every other week. The mean dose of
MTX and glucocorticoids did not differ during the treatment.
The disease activity of RA patients was assessed according to
the 28 joint count disease activity score (DAS28) using the
number of swollen and tender joints, ESR and patient’s global
visual analogue scale (VAS) [27]. Baseline characteristics of the
patients are provided in Table 1. The study was approved by the
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local ethics committee, and informed consent was obtained
from all patients.
Laboratory analyses
Blood samples were collected from all patients at baseline and,
additionally, from the adalimumab group at Weeks 6 and 12 after
initiation of therapy. Samples were immediately centrifuged and
stored at 208C until analysis. CRP was analysed by latex
immunoturbidimetric assay according to the manufacturer’s
protocol (Olympus, Prague, Czech Republic). Plasma S100A4
concentration was measured by a sandwich ELISA, as previously
described [21].
Size-exclusion chromatography (SEC) was carried out using a
Superdex 200 PC 3.2/30 column (Amersham Biosciences,
Hillerod, Denmark) with buffer A (50mM Tris–HCl pH 7.4,
144mM NaCl) as the mobile phase. The column was calibrated
using a gel filtration standard (Bio-Rad Laboratories, Prague,
Czech Republic) ranging from 1.35 to 670 kDa. The mixture
included thyroglobulin (670 kDa), bovine -globulin (158 kDa),
chicken ovalbumin (44 kDa), equine myoglobin (17 kDa) and
vitamin B12 (1.35 kDa). A plasma volume of 20l was applied
to the column. The chromatography profile was monitored
at 215 nm. Fractions of 50l were collected, snap-frozen in
liquid nitrogen and stored at 808C.
Stimulation of monocytes by S100A4
Human peripheral blood mononuclear cells were isolated from the
peripheral blood of healthy volunteers (n¼ 4) by Ficoll-Plaque
density gradient centrifugation. CD14þ monocytes were selected
positively using anti-CD14 microbeads (Miltenyi Biotec, Bergisch
Gladback, Germany). Monocytes were plated at 5.0 105 cells
(confluent cells condition) per 2ml of advanced RPMI medium
1640 (Invitrogen, Carlsbad, CA, USA) supplemented with
L-glutamine (Gibco, Carlsbad, CA, USA) in 35-mm diameter
culture plates. After plating, monocytes were incubated for
30min at 378C with 5% CO2 in a humidified atmosphere. Non-
adherent cells were eliminated by sterile PBS wash. Adherent
cells were treated with a S100A4 dimer (1g/ml) and multimer
(1g/ml) for 6 and 24 h. The S100A4 proteins were obtained from
recombinant His6-tagged protein by gel filtration [28]. The dose
and time course were selected in accordance with our previous
experiments [19, 21]. The incubation was terminated after 6 h
and cells were lysed by RLT buffer (Qiagen, Hilden, Germany)
and stored in 808C until RNA isolation. Cell culture super-
natants were collected after 24 h of exposure to S100A4 and
stored in 208C.
RT–PCR analysis
Total RNA from monocytes was extracted using the MagNA
Pure Compact RNA Isolation kit for MagNA Pure Compact
Instrument (Roche Diagnostics, Mannheim, Germany). Comple-
mentary DNA was obtained by reverse transcription using
RevertAid First Strand cDNA Synthesis Kit (Fermentas Life
Sciences, Vilnius, Lithuania). PCR was performed according to
a standard protocol. Pre-developed, commercially available pri-
mers (Applied Biosystems, Prague, Czech Republic) were used to
detect TNF- mRNA. The 18S rRNA was used to normalize the
results. Data were analysed using the comparative threshold cycle
(Ct) method for relative quantification, and the Ct for 18S samples
was subtracted from the Ct of the studied genes, giving the dCt
values. Real-time PCR was performed using the 7900HT Fast
Real-Time PCR System (Applied Biosystems).
ELISA
The levels of TNF- were measured in the cell culture super-
natants using an ELISA kit according to the manufacturer’s
protocol (Ray Biotech, Norcross, GA, USA). The analysis was
performed using a Sunrise ELISA reader (Tecan, Salzburg,
Austria) at a wavelength of 450 nm.
Statistical analyses
S100A4 protein concentrations were expressed as mean (S.E.M.).
Spearman’s rank correlation was used to correlate any two
variables. The Friedman analysis of variance test for repeated
measures and Mann–Whitney U-test for comparisons between
two measures were performed. For all statistical evaluations,
P-values <0.05 were considered as statistically significant.
Results
S100A4 protein and disease activity
Disease activity decreased significantly after treatment with
adalimumab [mean (S.D.) DAS28: 6.2 (0.7) (baseline) vs 3.8 (1.0)
(Week 6) vs 3.3 (0.9) (Week 12); P< 0.01]. The treatment was
clinically effective in 23 out of 25 RA patients ( DAS28: 51.2).
The baseline level of S100A4 in plasma correlated strongly with
the baseline DAS28 (r¼ 0.41; P< 0.01) (Fig. 1). However, no
correlations were observed between the S100A4 protein and the
DAS28 at Weeks 6 and 12 after the initiation of therapy, as well as
between the baseline S100A4 and the change in DAS28 between
baseline and Week 12 (r¼ 0.23; P¼ 0.26). Levels of S100A4
protein did not correlate with the baseline levels of CRP
(r¼0.17; P¼ 0.29), IgM RF (r¼ 0.02; P¼ 0.9) or with anti-
citrullinated protein/peptide antibodies (ACPAs) (r¼ 0.09;
P¼ 0.56). Likewise, these variables did not correlate with
S100A4 levels after the treatment (data not shown). Results
were indicative of a relationship between S100A4 protein and
the inflammatory activity, rather than with the autoimmune
response of the disease.
TABLE 1. Baseline characteristics of the patients with RA
Subgroup of RA
patients treated
with anti-TNF-
All RA patients—
anti-TNF- naive
Number 25 40
Gender (female/male) 21/4 34/6
Age, years 43.7 (10.3) 50.6 (13.3)
CRP, mg/l 38 (28.9) 29.9 (26.5)
DAS28 score 6.2 (0.7) 5.8 (1.2)
Drugs (MTX/GC) 19/16 28/27
ESR, mm/first h 39.8 (20.1) 34.3 (20.1)
S100A4, ng/ml 466.5 (306.1) 592 (458.3)
S100A4 concentrations are expressed as mean (S.E.M.). GC: glucocorticoids; DAS: disease
activity score; CRP: C-reactive protein Other values as mean (S.D.).
FIG. 1. Relationship between the baseline disease activity and plasma levels of the
metastasis-inducing protein S100A4 in patients with RA.
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The effect of TNF- inhibitor adalimumab on the plasma
S100A4 protein
S100A4 values in plasma of healthy individuals are normally in
the range of 50–300 (mean 80) ng/ml, as reported in our previous
study [21]. As shown in Fig. 2A, the total plasma levels of S100A4
were significantly higher, but not significantly affected by
adalimumab treatment [mean (S.E.M.) of baseline vs Week 6 vs
Week 12: 466.4 (66.5) vs 522.1 (58.4) vs 535.1 (96.8) ng/ml] in
patients with RA. Plasma samples from eight randomly selected
patients were subjected to SEC, and six of them demonstrated a
tendency to shift from the high to the low conformational form
after 12 weeks of adalimumab therapy. Two representative
profiles of the SEC are shown in Fig. 2B and C. One of the two
samples showing no clear conformational shift in S100A4
belonged to a patient who failed to achieve a clinically effective
response (Fig. 2D). Patients responding to the treatment with
adalimumab showed a clear shift in the conformations of
S100A4 from the multimeric and oligomeric forms to the dimeric
forms. In contrast, no such clear shift was observed in a patient
who experienced an inadequate response to the treatment with
adalimumab. This patient presented, instead, a tendency for an
increase in some multimeric and oligomeric S100A4 forms.
Therefore, it can be suggested that successful treatment of RA
patients yields the prompt conformational modifications of
the bioactive S100A4 multimer towards the less bioactive
S100A4 dimer.
S100A4 multimer up-regulates TNF- in human monocytes
To confirm the bioactivity of the S100A4 multimer, we stimulated
peripheral blood monocytes with the S100A4 multimer and dimer.
We then analysed the levels of TNF- mRNA after 6 h of
treatment and the levels of TNF- in supernatants after 24 h.
Four independent experiments were performed in duplicates.
The expression of TNF- mRNA was up-regulated by more
than three times in monocytes treated with the S100A4 multimer
compared with monocytes exposed to the S100A4 dimer
(P< 0.01) (Fig. 3A). In addition, the synthesis of TNF- by
monocytes was significantly increased in those samples treated
with the S100A4 multimer for 24 h, when compared with mono-
cytes stimulated with the S100A4 dimer and to unstimulated
monocytes [4474.6 (1282) vs 958.4 (706.2) vs 250.3 (165) pg/ml;
P< 0.001] (Fig. 3B).
Discussion
This study shows, for the first time, that the levels of the
metastasis-inducing protein, S100A4, are significantly correlated
with the disease activity of RA. In addition, we also showed that
only the bioactive S100A4 multimer, but not the total amount of
S100A4, appears to decline after successful TNF- blocking
therapy with adalimumab.
S100A4 protein has been mostly studied in cancers, particularly
with respect to its ability to enhance metastasis [23]. In addition,
recent data have linked S100A4 to the pathogenesis of RA. We
have demonstrated the up-regulation of S100A4 in the synovium,
SF and bloodstream of patients with RA. We have also shown
that this protein has a regulatory role within several pathogenic
aspects of the disease [19–21]. In contrast with other S100
proteins, S100A4 was not restricted to phagocytes, but also
co-localized with fibroblasts, several immune cells and vascular
cells [21]. The abundance of S100A4 in synovial tissue and SF
from patients with RA was consistent with the finding of high
concentrations of the protein in RA, compared with the
OA/control plasma samples [21]. Consequently, we have shown,
for the first time, a significant association between the S100A4
concentration and the RA disease activity. Our finding is consis-
tent with the data presented by Foell et al. [12] and Wulffraat et al.
[13], who found an association between other S100 proteins
FIG. 2. Modulation of metastasis-inducing protein S100A4 plasma levels in RA patients in response to the TNF- inhibitor adalimumab. Total plasma levels of S100A4
remained unchanged during the therapy (A). An obvious shift occurred in S100A4 from the high to the low molecular weight form, together with a decline in the bioactive
S100A4 multimer after 12 weeks of the therapy with adalimumab (B and C). However, no clear conformational shift of S100A4 from the high to the low (dimeric) molecular
weight, but rather a tendency for an increase of some multimeric and oligomeric S100A4 forms, was documented in a patient who experienced an inadequate response to
the treatment with adalimumab. The representative profile of the S100A4 conformational modulation is depicted in (D). The numbers on the x-axis represent 13 fractions of
S100A4 with different molecular weights (in kilodaltons) separated by size-exclusion chromatography. Each fraction corresponds to a certain S100A4 conformation,
for instance fr 13: 2-mer; fr. 11: 4-mer; fr. 9: 14mer; fr. 5: >60-mer. Trend lines are indicated.
1592 Lucie Osˇlejsˇkova´ et al.
(S100A12 and S100A8/9) and disease activity in patients with RA.
Furthermore, an association of S100A8/9 with autoantibodies,
including RF or ACPA, has been previously documented [29].
Nevertheless, we have found no significant correlation between
S100A4 and RF or ACPA antibodies. We have also not found
any correlation between S100A4 protein and CRP. Thereby, it can
be suggested that S100A4 reflects the disease activity as assessed
by all the components of DAS28 rather than the acute phase
response or the immune activation only.
It has been previously demonstrated that the concentrations of
S100A8/9 and S100A12 decrease significantly both at the local
and global (bloodstream) levels in patients with RA, following
TNF- blocking therapy [14, 16, 17]. Therefore, we expected
changes in the plasmatic S100A4 levels after TNF- blocking
therapy. Surprisingly, TNF- blocking with adalimumab did not
change plasma levels of the total S100A4 protein. S100A4 can
exist as a multimer or as a dimer. Several studies have demon-
strated that the dimer form of S100A4 resides intracellularly.
In contrast, the multimeric conformations, which are the
biologically active forms of S100A4 and which can therefore
trigger several cellular responses, reside mostly extracellularly
[28, 30]. By analysing the conformation of the S100A4 protein,
we observed a conformational shift from the bioactive multimers
to the less active, oligomeric and dimeric forms following
adalimumab therapy. To confirm the bioactivity of the S100A4
multimer [28, 30], we demonstrated that when compared with the
dimer, the S100A4 multimer, considerably up-regulated TNF-
gene expression and protein release by activated monocytes.
These results are in agreement with our previous reports
showing that only the S100A4 multimer, but not the dimer, was
capable of modulating the expression of matrix-degrading
enzymes and apoptotic molecules in synovial fibroblasts [19, 21].
Since multimers are considered as biologically active, we hypothe-
size that the down-regulation of the bioactive S100A4 protein
(multimer) could be associated with the improvement in disease
activity observed after TNF- blocking therapy. Moreover, our
unpublished in vitro data with synovial fibroblasts correspond
well with the results of Devoogdt et al. [31] in cancer cells,
which suggested that TNF- does not change the expression of
S100A4 mRNA. In addition, S100A4 mRNA is up-regulated in
monocytes from patients with RA, compared with healthy con-
trols. However, S100A4 mRNA does not appear to be modulated
by TNF- in human monocytes (L Oslejskova, unpublished data).
Thus, we suggest that S100A4 is regulated independently of
TNF-, and/or by post-translational modification, depending on
the inflammatory activity of the disease.
This study has some limitations. We have not correlated the
levels of S100A4 protein with the measures of joint damage.
Therefore, we could not postulate the potential predictive value
of S100A4 for further development of the disease, as demon-
strated recently for calprotectin [29, 32]. It is not yet possible to
quantify the S100A4 multimer and associate this form with the
disease activity of RA, a relationship that could be extremely
informative. Moreover, this study was designed to analyse the
association of S100A4 with the disease activity of RA and did
not include healthy controls for comparison. However, our
previous results have demonstrated a significant increase in
plasma S100A4 levels in patients with RA, compared with control
individuals [21].
In conclusion, we have demonstrated for the first time that the
levels of the metastasis-inducing protein S100A4, similar to alar-
mins S100A8/9 and S100A12, are significantly correlated with RA
disease activity. Furthermore, we have shown that the bioactive
S100A4 multimer, but not the total amount of S100A4, declines
after successful TNF- blocking therapy.
Rheumatology key messages
 The levels of the metastasis-inducing protein S100A4 in plasma
correlate with RA disease activity.
 Bioactive S100A4 multimer, but not the total amount of S100A4,
declines after successful TNF- blocking therapy.
 S100A4 multimer up-regulates TNF- gene expression and
protein release by activated monocytes in vitro.
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